Ruti Aga and the Six-Year Ban: How a Forged Prescription Rewrote a Marathon Career's Arithmetic

The first thing that happens after the finish line at a March label road race in China is not a look at the clock. The top finishers are walked to a holding tent — water, a chair, a form. The doping control officer hands over a notification slip, the athlete signs, two bottles are sealed, A and B, the seal numbers are cross-checked. Twenty minutes of procedure. Then the press area, then the flower ceremony, then the hotel. The woman in that tent had won the race. Nobody asked her about her knee.

On a Thursday in September, the Athletics Integrity Unit issued a statement. Ruti Aga, 32, Ethiopia, six-year ban. Two years for the presence of methylprednisolone, four years for the prescription she produced during the investigation. The ban runs from 10 September — the date of her provisional suspension, from which she was already out.

The detail that stops you on a first read is not the length of the sanction. It is that the prescription carried the letterhead of a clinic that did not exist, signed by a "doctor" who was a family member with no medical registration, who claimed to have used "an old prescription pad from a former workplace." The workplace disowned the claim.

This is not the story of a case that began with a bottle. It is the story of a case that began in an empty space where medical governance should have been, and ended in paperwork — and what gets lost in between is that the six years were earned by the paper, not the drug.

Context: the terrain where the doctor arrives after the medicine

London, 2026. I was a 19-year-old volunteer recorder at the World Championships, and the mixed zone after the women's 400m heats was almost empty, so I logged 27 interviews in 48 hours. In the stadium concourse I asked 50 spectators what they remembered. Forty-one named a medal. Not one named a women's split. Memory follows the medal table, and the medal table follows a structure nobody writes down.

Aga's case is a photograph of that structure. Ethiopia's women's marathon depth is such that a 2:18 runner cannot assume selection. The world-record tier sits at 2:11–2:12, and beneath it runs a queue of 2:14, 2:15, 2:16 athletes who win Majors in different years. The removal of a 32-year-old for six years does not change a single line in the national selection arithmetic. It has to be written coldly: this case is not about sporting competition. It is about the profession the athlete works inside.

There is no league in Ethiopian or Kenyan road running. There is no monthly salary. Income has three parts — an advance from an agent, an appearance fee, and prize money. The altitude camps, the club-agent network, the foreign race calendar: that is the real payroll. In Indian athletics the equivalent role is played by a Railways zone or a Services appointment. In East Africa it is played by the agent. In both places one thing is missing: a credentialed team physician who travels with the athlete and decides, before the race, when and by which route a knee injection is given.

China's label circuit is the brightest and least supervised edge of that structure. Large appearance-fee budgets, deep East African elite fields, less competitive pressure than a Major — for a 2:18–2:20 marathoner this is the middle economic tier. It is also where AIU testing yields most, because the athlete is present, being paid, and available for a sample. The appearance-fee economy and the testing economy are colliding in the same races. That March half marathon is the collision point.

No performance data from this case is public — no time, no splits, no field strength. The source says only that she won. So I will not do form analysis here. What is available is administrative: when the sample was taken, which substance was found, by what route it likely entered the body, and what document was produced under questioning. As a record-keeper, I will say plainly that the clock had no work to do in this report.

Core: the arithmetic of two plus four, and the error every report repeated

Begin with the technical correction, because without it the whole argument points the wrong way. Several reports described methylprednisolone as a "prohibited steroid" and said WADA classes it as performance enhancing. That is imprecise. Methylprednisolone is a glucocorticoid — WADA Prohibited List class S9 — not an anabolic steroid (class S1). The distinction is not decoration; it is the spine of the case.

S9 substances are prohibited in-competition only under the current List, and only by injection, oral or rectal routes. Inhalers and creams sit outside it. A therapeutic knee injection, given out of competition, is entirely legal. It becomes a violation only if residues are present on race day. A road race's testing window opens at 23:59 the day before, so an injection given days earlier can still be caught. Washout periods vary by route and dose; intra-articular residues can persist for days. (I should be explicit here: I could not verify the route-specific washout figures, so I am not presenting them as settled. The principle is settled — timing and route are the decisive variables.)

Which means Aga had a legitimate defence available. If the knee treatment was real and its records existed, the argument would not have been "steroid or no steroid" but "by which route, on which date, and was it medically necessary." A documentary defence with a route and timing explanation could have moved the case toward no-fault or no-significant-fault — potentially a reprimand or a substantially reduced period.

She destroyed that defence herself.

Now the arithmetic. Two years for presence, four for tampering, six in total. The structure matches standard Code sanctions. Two years means the panel accepted the substance was in her body but did not find intent — glucocorticoids are Specified Substances, which keeps that route open. Four years is the standard tampering sanction, and it was applied in full.

There is a paradox inside this arithmetic that few pick up. A forged prescription is itself circumstantial evidence of concealment intent. Yet it did not aggravate the presence sanction — that stayed at two years. The panel treated the drug as negligence and the paperwork as full culpability. The heavy money in this sanction was spent on the document, not the drug.

Three verification failures, and they are links in one chain, not separate accidents. First, the clinic on the prescription did not exist. Second, the person who signed it was a family member with no medical registration. Third, the claimed "old pad from a former workplace" was publicly disowned by that workplace. Three independent verification failures on one document. Any single one of them being true would have made this a different case.

The tampering charge matters for another reason: it did not arise from a document alone but from statements made during interview. The athlete was questioned, she offered an explanation, and the explanation collided with the paperwork. Language and translation conditions in AIU interviews with East African athletes have been a recurring point of contention. I am not claiming a translation failure here. I am noting that a 40-second answer given in a room became four years. A corridor answer and an interview-room answer are both primary sources; the difference is that nobody weighs the first and the second can end a career.

Backdating to 10 September is procedural relief, not a discount. Time served under provisional suspension counts against the ban; the athlete gains nothing real, only a date moved backwards on paper.

What survives? The 2026 Tokyo Marathon title, and three second-place finishes at World Marathon Majors. That is the record of a genuinely elite marathoner. The violation is anchored to the March race, and absent a finding of earlier use, results before that date are not automatically annulled. The statement also does not specify the disqualification scope. What is not stated I will not treat as stated — but standard practice is that the competition at which the sample was collected is disqualified, with prize money forfeited. The March win, and its cheque, are almost certainly gone.

Contrarian: six years for a drug that does not make a marathon faster

Here is the part I turned over longest, and I will write it from both sides because one side alone would be dishonest.

There is no established evidence that glucocorticoids improve marathon performance. They reduce inflammation, suppress pain, and put an injured runner on a start line. That is relief, not theft — and relief does affect performance, but the effect is "being able to race," not "racing faster." Media coverage erased that distinction when it called the substance a steroid. And the erasure does damage, because the word "steroid" converts a governance story into a morality story, and morality stories do not produce team doctors.

Equally, the disproportionality argument cannot be used to soften six years. In a documentary system, forgery is the real offence. If forged prescriptions become cheap and available, the entire TUE architecture collapses, because that architecture runs on trust that the paper is genuine. The four-year tampering sanction is the price of that trust. In a sport where verification is the only wall, the person who breaks the wall pays most.

An asymmetry still deserves recording. Tampering charges recur unusually often in East African road-running cases, and one reason is that these athletes lack the framework to understand where an investigation is heading. A European athlete has a lawyer, a manager, federation legal support and a credentialed medical team. An Ethiopian road runner often has an agent and a family. In a crisis, it is the family that tries to "arrange something" — and the arrangement doubles the sanction. That is not an excuse; it is a structure. And structures need doctors, not penalties.

One more parallel, because of how I work. Indian athletics had its own round of CAS-confirmed bans in 2026, including members of the relay generation that had peaked at Delhi 2026. The problem then was not the drug either; it was ignorance and a reflex to cover up, and that reflex was institutional rather than a character flaw in individuals. Anyone who has stood at a Federation Cup final will recognise the pattern: the first crisis comes from the absence of medical support, the second from the attempt to hide it. Aga's case is the second stage, in Amharic and Oromo rather than English.

And a final asymmetry, the least comfortable. Six years is an age penalty. A 32-year-old returns at 38. In Ethiopian women's marathon depth, no selector has a reason to pick a 38-year-old returning with a doping record. On paper the ban is six years; in practice it is the end of a career. The sanction is written as six years, but its real unit is age — and age has no appeal.

The ledger we forget: second places

In March 2026 I watched the World U20 Championships in Tampere on a laptop in a London student union common room. Hima Das won the 400m, and I hosted a 90-minute watch-along for 34 students; 22 stayed for the Q&A. The chat kept asking about her village and her family, not her stride rate. I rebuilt the segment around that.

What that night taught me applies directly here: spectators remember an athlete by her place, not by her time. And when an athlete has no place — no recorded village, club, agent, physician — what remains to remember is either a medal or a controversy.

Aga has no global championship medal. Not one. What she has is three Major second places and the 2026 Tokyo win. In that London concourse in 2026, 41 people gave me a medal and none gave me a split. If I asked 50 marathon fans today who won the women's race in Tokyo 2026, some names would come. If I asked who was second, third and fourth, the room would go quiet. This is the real deficit in women's sport — we do not keep a ledger for fourth place, and we certainly do not keep one for second. P. T. Usha's 55.42 in Los Angeles in 2026, one hundredth off bronze, is remembered because a whole state insisted on remembering it. Krishna Poonia's Delhi 2026 discus gold slid out of the mainstream inside a month. Memory follows infrastructure.

Aga will now be remembered through a different door — controversy. The irony is that the controversy gave her a recognition three Major podiums never did.

What comes next: the enforcement frontier has moved from detection to verification

The first phase of anti-doping was detection — better testing, biological passports, more out-of-competition samples. The second phase, already underway, is verification. The cluster forming in AIU road-running cases usually has a substance violation first and an explanation second, and it is the explanation that doubles the sanction. That is partly good news: the system is cross-checking statements against documents. It is also a warning: athletes racing without credentialed medical support now carry two risks — one for the medicine, one for the paperwork.

The consequence should be that agents and management companies start treating a credentialed physician as insurance rather than cost. The day that happens, cases like this fall away. Until it does, every injured marathoner has the same two options: run through the pain, or have a relative "arrange something."

One question remains, and it comes not from a statement but from the silence around one. Nothing came from the Ethiopian federation. Nothing about the agent. Nothing about the medical network that produced the prescription. Only the AIU spoke, and only one athlete was named.

At London 2026 I learned that the most important thing usually happens outside the room with the cameras. In that tent in March, while the bottles were being sealed, one question could have been asked: who treated your knee? Had it been asked that day — by an official, a reporter, an agent — the Thursday in September might never have arrived.

The next time a woman wins a label race in China and walks toward the tent past the finish line, one question should travel with her, ahead of the clock: who is looking after her, and who is paying for it? The day that question becomes part of the mixed zone, there will be fewer six-year bans.